Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 14/20 | 0.71 |
| ▸ | ADK | P55263 | 1/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.41 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524256 | 0.84 | AHCY (0.67) | AHCYADORA2BDNMT1DNMT3B | |
| SCHEMBL20191359 | 0.83 | AHCY (1.00) | AHCYADORA2B | |
| SCHEMBL10431839 | 0.80 | AHCY (0.65) | AHCY | |
| SCHEMBL14635767 | 0.77 | AHCY (1.00) | AHCYMTORRAB9AADORA2B | |
| SCHEMBL12149497 | 0.76 | AHCY (0.68) | AHCYADORA2BDNMT1DNMT3B | |
| SCHEMBL9679135 | 0.75 | AHCY (0.80) | AHCYADORA2BDNMT1DNMT3B | |
| SCHEMBL24686947 | 0.73 | ADORA2A (0.54) | AHCYADORA2B | |
| SCHEMBL21057423 | 0.73 | AHCY (0.71) | AHCYADORA2BDNMT1DNMT3B | |
| SCHEMBL21057389 | 0.72 | AHCY (0.53) | AHCYADORA2B | |
| SCHEMBL21057360 | 0.72 | AHCY (0.53) | AHCYADORA2BDNMT1DNMT3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | claimed |
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | ADK, AHCY, IAPP | AHCY 2/4885ADK 1/4885MTOR 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.